Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Feb;39(2):520–524. doi: 10.1128/aac.39.2.520

Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections.

C Peña 1, J M Albareda 1, R Pallares 1, M Pujol 1, F Tubau 1, J Ariza 1
PMCID: PMC162571  PMID: 7726525

Abstract

From 1988 to 1992, 27 of 855 cases of Escherichia coli bacteremia in nonneutropenic adult patients observed at our hospital were due to ciprofloxacin-resistant (CIPRO-R) strains. Eighteen episodes (67%) were community acquired, and nine (33%) were nosocomially acquired. Overall, the rates of E. coli bacteremia caused by CIPRO-R strains increased steadily from 0% in 1988 to 7.5% in 1992 (P < 0.01). There was a statistically significant correlation between the incidence of CIPRO-R E. coli bacteremia and the upward trend in fluoroquinolone (norfloxacin and ciprofloxacin) use in the community (r = 0.974; P = 0.005) as well as in the hospital (r = 0.975; P = 0.005). When we compared the 27 case patients with 54 simultaneous control patients who had ciprofloxacin-susceptible E. coli bacteremia, the case patients more frequently had chronic underlying diseases (71 versus 37%; P = 0.004), urinary tract infection (74 versus 50%; P = 0.03), prior surgery (22 versus 6%; P = 0.02), and prior fluoroquinolone use (63 versus 4%; P < 0.001). A logistic regression analysis identified prior quinolone use as the only independent risk factor for CIPRO-R E. coli bacteremia. In conclusion, our study shows a significant correlation between ciprofloxacin resistance and fluoroquinolone use and indicates that prior fluoroquinolone use seems to be the most important risk factor for CIPRO-R E. coli bacteremia.

Full Text

The Full Text of this article is available as a PDF (613.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aguiar J. M., Chacon J., Canton R., Baquero F. The emergence of highly fluoroquinolone-resistant Escherichia coli in community-acquired urinary tract infections. J Antimicrob Chemother. 1992 Mar;29(3):349–350. doi: 10.1093/jac/29.3.349. [DOI] [PubMed] [Google Scholar]
  2. Baquero F. Resistance to quinolones in gram-negative microorganisms: mechanisms and prevention. Eur Urol. 1990;17 (Suppl 1):3–12. doi: 10.1159/000464084. [DOI] [PubMed] [Google Scholar]
  3. Barry A. L., Fuchs P. C., Pfaller M. A., Allen S. D., Gerlach E. H. Prevalence of fluoroquinolone-resistant bacterial isolates in four medical centers during the first quarter of 1990. Eur J Clin Microbiol Infect Dis. 1990 Dec;9(12):906–908. doi: 10.1007/BF01967511. [DOI] [PubMed] [Google Scholar]
  4. Blumberg H. M., Rimland D., Carroll D. J., Terry P., Wachsmuth I. K. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis. 1991 Jun;163(6):1279–1285. doi: 10.1093/infdis/163.6.1279. [DOI] [PubMed] [Google Scholar]
  5. Chapman J. S., Georgopapadakou N. H. Routes of quinolone permeation in Escherichia coli. Antimicrob Agents Chemother. 1988 Apr;32(4):438–442. doi: 10.1128/aac.32.4.438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cohen S. P., Hooper D. C., Wolfson J. S., Souza K. S., McMurry L. M., Levy S. B. Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrob Agents Chemother. 1988 Aug;32(8):1187–1191. doi: 10.1128/aac.32.8.1187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cometta A., Calandra T., Bille J., Glauser M. P. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med. 1994 Apr 28;330(17):1240–1241. doi: 10.1056/NEJM199404283301717. [DOI] [PubMed] [Google Scholar]
  8. Dupeyron C., Mangeney N., Sedrati L., Campillo B., Fouet P., Leluan G. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother. 1994 Feb;38(2):340–344. doi: 10.1128/aac.38.2.340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Greenwood D., Osman M., Goodwin J., Cowlishaw W. A., Slack R. Norfloxacin: activity against urinary tract pathogens and factors influencing the emergence of resistance. J Antimicrob Chemother. 1984 Apr;13(4):315–323. doi: 10.1093/jac/13.4.315. [DOI] [PubMed] [Google Scholar]
  10. Heisig P., Tschorny R. Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro. Antimicrob Agents Chemother. 1994 Jun;38(6):1284–1291. doi: 10.1128/aac.38.6.1284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hirai K., Aoyama H., Suzue S., Irikura T., Iyobe S., Mitsuhashi S. Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother. 1986 Aug;30(2):248–253. doi: 10.1128/aac.30.2.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hooper D. C., Wolfson J. S., Ng E. Y., Swartz M. N. Mechanisms of action of and resistance to ciprofloxacin. Am J Med. 1987 Apr 27;82(4A):12–20. [PubMed] [Google Scholar]
  13. Kern W. V., Andriof E., Oethinger M., Kern P., Hacker J., Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother. 1994 Apr;38(4):681–687. doi: 10.1128/aac.38.4.681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kern W. V., Markus A., Andriof E. Bacteremia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients. Eur J Clin Microbiol Infect Dis. 1994 Feb;13(2):161–165. doi: 10.1007/BF01982191. [DOI] [PubMed] [Google Scholar]
  15. Kresken M., Jansen A., Wiedemann B. Prevalence of resistance of aerobic gram-negative bacilli to broad-spectrum antibacterial agents: results of a multicentre study. J Antimicrob Chemother. 1990 Jun;25(6):1022–1024. doi: 10.1093/jac/25.6.1022. [DOI] [PubMed] [Google Scholar]
  16. Kresken M., Wiedemann B. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. Antimicrob Agents Chemother. 1988 Aug;32(8):1285–1288. doi: 10.1128/aac.32.8.1285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Muder R. R., Brennen C., Goetz A. M., Wagener M. M., Rihs J. D. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center. Antimicrob Agents Chemother. 1991 Feb;35(2):256–258. doi: 10.1128/aac.35.2.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ogle J. W., Reller L. B., Vasil M. L. Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe. J Infect Dis. 1988 Apr;157(4):743–748. doi: 10.1093/infdis/157.4.743. [DOI] [PubMed] [Google Scholar]
  19. Piddock L. J., Wise R. The effect of altered porin expression in Escherichia coli upon susceptibility to 4-quinolones. J Antimicrob Chemother. 1986 Oct;18(4):547–549. doi: 10.1093/jac/18.4.547. [DOI] [PubMed] [Google Scholar]
  20. Pérez-Trallero E., Urbieta M., Jimenez D., García-Arenzana J. M., Cilla G. Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections. Eur J Clin Microbiol Infect Dis. 1993 May;12(5):349–351. doi: 10.1007/BF01964432. [DOI] [PubMed] [Google Scholar]
  21. Watanabe M., Kotera Y., Yosue K., Inoue M., Mitsuhashi S. In vitro emergence of quinolone-resistant mutants of Escherichia coli, Enterobacter cloacae, and Serratia marcescens. Antimicrob Agents Chemother. 1990 Jan;34(1):173–175. doi: 10.1128/aac.34.1.173. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES